Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 260.50K | $ 123.44K | $ 3.10M | $ 698.47K |
| Gross Profit | $ 0.00 | $ -13.36M | $ 116.72K | $ -8.26M | $ -195.33K |
| Operating Income | $ -28.59M | $ -20.09M | $ -18.13M | $ -14.77M | $ -2.82M |
| EBITDA | $ -28.59M | $ -19.91M | $ -18.12M | $ -14.77M | $ -2.82M |
| Net Income | $ -27.52M | $ -19.03M | $ -17.91M | $ -14.81M | $ -2.88M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 97.54M | $ 13.25M | $ 23.05M | $ 40.75M | $ 13.95M |
| Total Assets | $ 98.60M | $ 14.51M | $ 24.94M | $ 42.47M | $ 14.78M |
| Total Debt | $ 110.52K | $ 622.00K | $ 351.29K | $ 248.91K | $ 319.00K |
| Net Debt | $ -56.38M | $ -8.54M | $ -6.84M | $ -40.50M | $ -13.63M |
| Total Liabilities | $ 3.73M | $ 3.53M | $ 3.90M | $ 4.05M | $ 5.00M |
| Stockholders' Equity | $ 94.87M | $ 10.98M | $ 21.04M | $ 38.42M | $ 9.78M |
| Cash Flow | |||||
| Free Cash Flow | $ -19.15M | $ -18.10M | $ -17.59M | $ -14.30M | $ -1.13M |
| Operating Cash Flow | $ -19.15M | $ -18.09M | $ -17.35M | $ -14.30M | $ -1.13M |
| Investing Cash Flow | $ -37.00M | $ 11.66M | $ -16.01M | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 103.48M | $ 8.41M | $ -204.77K | $ 41.09M | $ 15.06M |
Inhibikase Therapeutics Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.